Baidu
map

糖尿病

订阅

MedSci主页 / 所有栏目 / 糖尿病

Kidney Int：对于2型糖尿病患者磺脲类药物致肾损伤的风险高于二甲双胍

2012-04-09 邵佩 中国医学论坛报

2型糖尿病肾损伤二甲双胍
关注

　　美国一项研究显示，与使用二甲双胍相比，口服磺脲类药物的2型糖尿病患者发生估计的肾小球滤过率（eGFR）下降、终末期肾脏病（ESRD）和死亡的风险增加。论文发表于4月期《国际肾脏病杂志》[Kidney Int 2012，81（7）:698]。    

　　美国一项研究显示，与使用二甲双胍相比，口服磺脲类药物的2型糖尿病患者发生估计的肾小球滤过率（eGFR）下降、终末期肾脏病（ESRD）和死亡的风险增加。论文发表于4月期《国际肾脏病杂志》[Kidney Int 2012，81（7）:698]。



    

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1383114, encodeId=2da01383114cd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396676, encodeId=21b013966e62f, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442130, encodeId=b13e144213023, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473633, encodeId=bc3314e363324, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602936, encodeId=edcd160293604, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=)]
    2012-04-11 aids213

    #2型糖尿病患者#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1383114, encodeId=2da01383114cd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396676, encodeId=21b013966e62f, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442130, encodeId=b13e144213023, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473633, encodeId=bc3314e363324, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602936, encodeId=edcd160293604, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=)]
    2012-04-11 智者为医08

    #损伤#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1383114, encodeId=2da01383114cd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396676, encodeId=21b013966e62f, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442130, encodeId=b13e144213023, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473633, encodeId=bc3314e363324, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602936, encodeId=edcd160293604, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=)]
    2012-04-11 passed water

    #磺脲类#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1383114, encodeId=2da01383114cd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396676, encodeId=21b013966e62f, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442130, encodeId=b13e144213023, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473633, encodeId=bc3314e363324, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602936, encodeId=edcd160293604, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=)]
    2012-04-11 xue8604

    #糖尿病患者#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1383114, encodeId=2da01383114cd, content=<a href='/topic/show?id=196a1101f7' target=_blank style='color:#2F92EE;'>#2型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1101, encryptionId=196a1101f7, topicName=2型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396676, encodeId=21b013966e62f, content=<a href='/topic/show?id=8bee565436d' target=_blank style='color:#2F92EE;'>#损伤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56543, encryptionId=8bee565436d, topicName=损伤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1442130, encodeId=b13e144213023, content=<a href='/topic/show?id=802ce3883fa' target=_blank style='color:#2F92EE;'>#磺脲类#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73883, encryptionId=802ce3883fa, topicName=磺脲类)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3064911832, createdName=passed water, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473633, encodeId=bc3314e363324, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602936, encodeId=edcd160293604, content=<a href='/topic/show?id=81b91049067' target=_blank style='color:#2F92EE;'>#kidney#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10490, encryptionId=81b91049067, topicName=kidney)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c36e18990621, createdName=gwc389, createdTime=Wed Apr 11 05:38:00 CST 2012, time=2012-04-11, status=1, ipAttribution=)]
    2012-04-11 gwc389

    #kidney#

    0

相关资讯

胃旁路术与胆胰转流术均能较好控制糖尿病大鼠血糖水平

　　日前，上海交通大学附属上海第六人民医院普外科狄建忠、韩晓东、张宏玮等人共同发表论文，旨在比较胃旁路术(GBP)与胆胰转流术(BPD)对非胰岛素依赖性糖尿病大鼠的治疗效果，探讨其机制。研究指出，GBP和BPD均能较好地控制糖尿病大鼠的血糖水平，其机制可能与瘦素的降低及IGF-1的升高有关。GBP在手术时间、死亡率及增加血IGF-1水平等方面优于BPD。该文发表在2011年第11卷第5期《中华胰腺

诺华维格列汀（佳维乐）在中国上市

 2月2日，维格列汀北京上市会隆重召开，为其成为我国2型糖尿病治疗新选择拉开了帷幕。二肽基肽酶4（DPP-4）抑制剂维格列汀（佳维乐）是一种新型2型糖尿病治疗药物，可同时改善胰岛α和β细胞功能障碍，具有强效降糖、无重度低血糖风险、不增加体重等特点。解放军总医院潘长玉教授和北京大学第一医院高妍教授担任会场主席，糖尿病临床负责研发维格列汀的科学家James E. Foley（詹姆斯·福莱）教

荟萃分析：40种基因突变与2型糖尿病风险有关

 2型糖尿病（T2D）影响了全球近3亿人，而多种基因和环境因素可与T2D相互影响。目前大部分的基因突变仍未被发现。由多国研究人员组成的研究联合会进行了一项有史以来规模最大的T2D基因研究，确定了与常见代谢性疾病风险有关的新基因突变型，该研究结果可用于研发更高效的治疗T2D药物。文献在线发表于《美国人类遗传学杂志》上[The American Society of Human Geneti

白米饭之“祸”？

图  糙米的结构和作用 　　最近，美国一项研究显示，食用较多的白米与2型糖尿病发生风险显著增加相关，这在亚洲人群（中国人和日本人）中尤其明显；在亚洲人中，与食用白米最少的人群相比，食用量最高人群发生2型糖尿病的汇总相对危险度（RR）为1.55；而在西方人中，相应的RR为1.12（P=0.038）；在全部人群中，若每天多食用1份白米（等同于158 g米饭），则发生2型糖尿病的R

Baidu
map
Baidu
map
Baidu
map